STAT July 19, 2024
David Gillum, Rebecca Moritz, Gregory D. Koblentz

In an era of rapid scientific and technological advances when politicians and scientists are struggling to find the right balance between innovation and safety, Sen. Rand Paul (R-Ky.) has introduced the Risky Research Review Act (S. 4667) in an effort to navigate this treacherous terrain. But instead of providing clarity and security, this legislation threatens to cast a shadow over the future of life sciences research and slow it down.

The act proposes creating a Life Sciences Research Security Board to review federally funded life sciences research involving “high-risk” experiments and to decide if such research should be funded. But the bill’s definition of high-risk life sciences research is overly broad and ambiguous, and duplicative of existing regulations covering agents...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Congress / White House, Govt Agencies
What to know about Trump's surgeon general nominee
President-elect Trump's picks for CDC, FDA, surgeon general: 31 notes
Trump's pick for CDC director: 10 things to know
Trump tariffs could drive up generic drug costs: 5 takeaways
Senators urge Congress to avert Medicare physician pay cut

Share This Article